GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn.
Source: Sharecast
IDRx specialises in developing treatments for gastrointestinal stromal tumours (GIST), GSK will pay $1bn up front with the potential for a further milestone payment of $150m.
Reporting by Frank Prenesti for Sharecast.com
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.